Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Payables (2022 - 2025)

Corvus Pharmaceuticals has reported Payables over the past 4 years, most recently at $1.2 million for Q3 2025.

  • Quarterly results put Payables at $1.2 million for Q3 2025, down 33.64% from a year ago — trailing twelve months through Sep 2025 was $1.2 million (down 33.64% YoY), and the annual figure for FY2024 was $2.6 million, up 69.31%.
  • Payables for Q3 2025 was $1.2 million at Corvus Pharmaceuticals, up from $730000.0 in the prior quarter.
  • Over the last five years, Payables for CRVS hit a ceiling of $4.2 million in Q3 2022 and a floor of $730000.0 in Q2 2025.
  • Median Payables over the past 4 years was $1.6 million (2024), compared with a mean of $1.9 million.
  • Biggest five-year swings in Payables: plummeted 66.78% in 2023 and later soared 69.31% in 2024.
  • Corvus Pharmaceuticals' Payables stood at $2.0 million in 2022, then decreased by 22.82% to $1.5 million in 2023, then soared by 69.31% to $2.6 million in 2024, then plummeted by 51.86% to $1.2 million in 2025.
  • The last three reported values for Payables were $1.2 million (Q3 2025), $730000.0 (Q2 2025), and $1.3 million (Q1 2025) per Business Quant data.